Antihypertensive Use and the Risk of Alzheimer's Disease and Related Dementias among Older Adults in the USA
Title
Antihypertensive Use and the Risk of Alzheimer's Disease and Related Dementias among Older Adults in the USA
Creator
Xi Pan
Donglan Zhang
Ji Haeng Heo
Chanhyun Park
Gang Li
Christine M Dengler-Crish
Yan Li
Yian Gu
Henry N Young
Devin L Lavender
Lu Shi
Date
2022
Description
Background: Epidemiological evidence on different classes of antihypertensives and risks of Alzheimer's disease and related dementias (ADRD) is inconclusive and limited. This study examined the association between antihypertensive use (including therapy type and antihypertensive class) and ADRD diagnoses among older adults with hypertension.
Methods: A retrospective, cross-sectional study was conducted, involving 539 individuals aged ≥ 65 years who used antihypertensives and had ADRD diagnosis selected from 2013 to 2018 Medical Expenditure Panel Survey (MEPS) data. The predictors were therapy type (monotherapy or polytherapy) and class of antihypertensives defined using Multum Lexicon therapeutic classification (with calcium channel blockers [CCBs] as the reference group). Weighted logistic regression was used to assess the relationships of therapy type and class of antihypertensives use with ADRD diagnosis, adjusting for sociodemographic characteristics and health status.
Results: We found no significant difference between monotherapy and polytherapy on the odds of ADRD diagnosis. As to monotherapy, those who used angiotensin-converting enzyme inhibitors (ACEIs) had significantly lower odds of developing AD compared to those who used CCBs (OR 0.36, 95 % CI 0.13-0.99).
Conclusions: Findings of the study suggest the need for evidence-based drug therapy to manage hypertension in later adulthood and warrant further investigation into the mechanism underlying the protective effect of antihypertensives, particularly ACEIs, against the development of AD among older adults with hypertension.
Methods: A retrospective, cross-sectional study was conducted, involving 539 individuals aged ≥ 65 years who used antihypertensives and had ADRD diagnosis selected from 2013 to 2018 Medical Expenditure Panel Survey (MEPS) data. The predictors were therapy type (monotherapy or polytherapy) and class of antihypertensives defined using Multum Lexicon therapeutic classification (with calcium channel blockers [CCBs] as the reference group). Weighted logistic regression was used to assess the relationships of therapy type and class of antihypertensives use with ADRD diagnosis, adjusting for sociodemographic characteristics and health status.
Results: We found no significant difference between monotherapy and polytherapy on the odds of ADRD diagnosis. As to monotherapy, those who used angiotensin-converting enzyme inhibitors (ACEIs) had significantly lower odds of developing AD compared to those who used CCBs (OR 0.36, 95 % CI 0.13-0.99).
Conclusions: Findings of the study suggest the need for evidence-based drug therapy to manage hypertension in later adulthood and warrant further investigation into the mechanism underlying the protective effect of antihypertensives, particularly ACEIs, against the development of AD among older adults with hypertension.
Source
Drugs Aging
. 2022 Nov;39(11):875-886. doi: 10.1007/s40266-022-00981-8. Epub 2022 Oct 17.
. 2022 Nov;39(11):875-886. doi: 10.1007/s40266-022-00981-8. Epub 2022 Oct 17.
Language
English
URL
https://doi.org/10.1007/s40266-022-00981-8
Citation
Xi Pan et al., “Antihypertensive Use and the Risk of Alzheimer's Disease and Related Dementias among Older Adults in the USA,” NEOMED Bibliography Database, accessed May 7, 2024, https://neomed.omeka.net/items/show/12156.